{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:12:25Z","timestamp":1788642745232,"version":"build-2803163510"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100014761","name":"Natural Science Foundation of Qingdao Municipality","doi-asserted-by":"publisher","award":["25-1-1-229-zyyd-jch"],"award-info":[{"award-number":["25-1-1-229-zyyd-jch"]}],"id":[{"id":"10.13039\/501100014761","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01411-2","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:10:34Z","timestamp":1788595834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody-Drug Conjugates in the Treatment of Esophageal Cancer"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-8365","authenticated-orcid":false,"given":"Dapeng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0958-0905","authenticated-orcid":false,"given":"Wenjing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"issue":"3","key":"1411_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1411_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2022","unstructured":"Morgan E, Soerjomataram I, Rumgay H, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163(3):649\u2013e6582.","journal-title":"Gastroenterology"},{"issue":"1","key":"1411_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"10302","key":"1411_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"5","key":"1411_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"key":"1411_CR6","doi-asserted-by":"publisher","first-page":"101152","DOI":"10.1016\/j.currproblcancer.2024.101152","volume":"53","author":"A Jubashi","year":"2024","unstructured":"Jubashi A, Kotani D, Kojima T, Takebe N, Shitara K. Current landscape of targeted therapy in esophageal squamous cell carcinoma. Curr Probl Cancer. 2024;53:101152.","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"1411_CR7","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/S1470-2045(23)00215-2","volume":"24","author":"E Van Cutsem","year":"2023","unstructured":"Van Cutsem E, di Bartolomeo M, Smyth E, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744\u201356.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1411_CR8","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1200\/JCO.22.00575","volume":"41","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial. J Clin Oncol. 2023;41(4):816\u201325.","journal-title":"J Clin Oncol"},{"key":"1411_CR9","doi-asserted-by":"publisher","first-page":"156032","DOI":"10.1016\/j.prp.2025.156032","volume":"271","author":"Z Yao","year":"2025","unstructured":"Yao Z, Wei G, Song P, et al. Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies. Pathol Res Pract. 2025;271:156032.","journal-title":"Pathol Res Pract"},{"issue":"23","key":"1411_CR10","doi-asserted-by":"publisher","first-page":"3764","DOI":"10.3390\/cancers17233764","volume":"17","author":"A Dominguez Wiscovitch","year":"2025","unstructured":"Dominguez Wiscovitch A, Sanchez Mendez RJ, Chuy J. CLDN18.2-Targeted Therapy in Gastrointestinal Cancers. Cancers (Basel). 2025;17(23):3764.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"1411_CR11","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/s13277-015-4132-5","volume":"37","author":"L Wang","year":"2016","unstructured":"Wang L, Cao NN, Wang S, Man HW, Li PF, Shan BE. Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma. Tumour Biol. 2016;37(3):2961\u201371.","journal-title":"Tumour Biol"},{"issue":"10","key":"1411_CR12","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/s41591-025-03792-7","volume":"31","author":"C Liu","year":"2025","unstructured":"Liu C, Liu D, Ji Y, et al. A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2025;31(10):3485\u201391.","journal-title":"Nat Med"},{"issue":"9","key":"1411_CR13","first-page":"e1648","volume":"26","author":"EY Jen","year":"2021","unstructured":"Jen EY, Ko CW, Lee JE, et al. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia. Oncologist. 2021;26(9):e1648\u201358.","journal-title":"Oncologist"},{"issue":"11","key":"1411_CR14","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1158\/1535-7163.MCT-20-0423","volume":"19","author":"FW Hunter","year":"2020","unstructured":"Hunter FW, Barker HR, Lipert B, et al. Mechanisms of Resistance to Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Mol Cancer Ther. 2020;19(11):2245\u201355.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1411_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM. Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol. 2024;21(3):203\u201323.","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"1411_CR16","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"26","key":"1411_CR17","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1080\/14796694.2025.2569553","volume":"21","author":"S Hurvitz","year":"2025","unstructured":"Hurvitz S, Simonelli M, Yarza R, et al. Beamion BCGC-1: phase Ib\/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers. Future Oncol. 2025;21(26):3385\u201393.","journal-title":"Future Oncol"},{"issue":"24","key":"1411_CR18","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.3390\/cancers17243987","volume":"17","author":"NB Raftery","year":"2025","unstructured":"Raftery NB, Ward M, Ravi N, Reynolds JV, Elliott JA, Donohoe CL. Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes. Cancers (Basel). 2025;17(24):3987.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1411_CR19","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.3390\/ijms25073876","volume":"25","author":"M Bonomi","year":"2024","unstructured":"Bonomi M, Spada D, Baiocchi GL, Celotti A, Brighenti M, Grizzi G. Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice. Int J Mol Sci. 2024;25(7):3876.","journal-title":"Int J Mol Sci"},{"issue":"30","key":"1411_CR20","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1080\/14796694.2025.2589996","volume":"21","author":"A Jubashi","year":"2025","unstructured":"Jubashi A, Nakayama I, Shitara K. Trastuzumab deruxtecan in the treatment of HER2-positive gastric cancer: a comprehensive review. Future Oncol. 2025;21(30):4043\u201356.","journal-title":"Future Oncol"},{"issue":"25","key":"1411_CR21","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419\u201330.","journal-title":"N Engl J Med"},{"issue":"4","key":"1411_CR22","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336\u201348.","journal-title":"N Engl J Med"},{"key":"1411_CR23","doi-asserted-by":"publisher","first-page":"847835","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X. Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers. Front Mol Biosci. 2022;9:847835.","journal-title":"Front Mol Biosci"},{"issue":"20","key":"1411_CR24","doi-asserted-by":"publisher","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","volume":"22","author":"Y Ogitani","year":"2016","unstructured":"Ogitani Y, Aida T, Hagihara K, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097\u2013108.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1411_CR25","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.3390\/cancers17243987","volume":"17","author":"NB Raftery","year":"2025","unstructured":"Raftery NB, Ward M, Ravi N, Reynolds JV, Elliott JA, Donohoe CL. Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes. Cancers (Basel). 2025;17(24):3987.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1411_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","volume":"18","author":"PC Thuss-Patience","year":"2017","unstructured":"Thuss-Patience PC, Shah MA, Ohtsu A, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study. Lancet Oncol. 2017;18(5):640\u201353.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1411_CR27","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s10120-018-00923-7","volume":"22","author":"MA Shah","year":"2019","unstructured":"Shah MA, Kang YK, Thuss-Patience PC, et al. Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric\/gastroesophageal junction cancer. Gastric Cancer. 2019;22(4):803\u201316.","journal-title":"Gastric Cancer"},{"issue":"10","key":"1411_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1358\/dot.2022.58.10.3408812","volume":"58","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhu Y, Wei X, Tang C, Zhang W. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors. Drugs Today (Barc). 2022;58(10):491\u2013507.","journal-title":"Drugs Today (Barc)"},{"issue":"1","key":"1411_CR29","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","volume":"29","author":"F Shi","year":"2022","unstructured":"Shi F, Liu Y, Zhou X, et al. Distamab vedotin: A novel antibody-drug conjugates for cancer therapy. Drug Deliv. 2022;29(1):1335\u201344.","journal-title":"Drug Deliv"},{"issue":"1","key":"1411_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/curroncol33010002","volume":"33","author":"Z Shi","year":"2025","unstructured":"Shi Z, Wang Y, Wang Y, et al. Real-World Efficacy and Safety of Disitamab Vedotin (RC48-ADC) in the Treatment of HER2-Overexpressing Advanced Gastric\/Gastroesophageal Junction Cancer. Curr Oncol. 2025;33(1):2.","journal-title":"Curr Oncol"},{"issue":"11","key":"1411_CR31","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","volume":"41","author":"Z Peng","year":"2021","unstructured":"Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173\u201382.","journal-title":"Cancer Commun (Lond)"},{"issue":"16suppl","key":"1411_CR32","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1200\/JCO.2025.43.16_suppl.4059","volume":"43","author":"S Li","year":"2025","unstructured":"Li S, Liu Z, Liu Y, et al. Disitamab vedotin (RC48), tislelizumab, and S-1 as first-line therapy for HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma: Updated results from the RCTS trial. J Clin Oncol. 2025;43(16suppl):4059.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1411_CR33","doi-asserted-by":"publisher","first-page":"2569994","DOI":"10.1080\/07853890.2025.2569994","volume":"57","author":"X Yan","year":"2025","unstructured":"Yan X, Xie Z, Ouyang K, et al. Disitamab vedotin plus programmed death-1 inhibitor for pre-treated HER2 overexpressed advanced gastric cancer: a multicentre retrospective real-world study. Ann Med. 2025;57(1):2569994.","journal-title":"Ann Med"},{"key":"1411_CR34","doi-asserted-by":"publisher","first-page":"102415","DOI":"10.1016\/j.eclinm.2023.102415","volume":"68","author":"Y Wang","year":"2024","unstructured":"Wang Y, Gong J, Wang A, et al. Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial. EClinicalMedicine. 2024;68:102415.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"1411_CR35","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1158\/1535-7163.MCT-19-1004","volume":"19","author":"L Skidmore","year":"2020","unstructured":"Skidmore L, Sakamuri S, Knudsen NA, et al. ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers. Mol Cancer Ther. 2020;19(9):1833\u201343.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1411_CR36","doi-asserted-by":"publisher","first-page":"100814","DOI":"10.1016\/j.xcrm.2022.100814","volume":"3","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Qiu MZ, Wang JF, et al. Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma. Cell Rep Med. 2022;3(11):100814.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1411_CR37","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41419-025-08278-5","volume":"17","author":"X Liu","year":"2025","unstructured":"Liu X, Liu J, Zhou Y, et al. A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway. Cell Death Dis. 2025;17(1):67.","journal-title":"Cell Death Dis"},{"issue":"19","key":"1411_CR38","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.3390\/cancers14194789","volume":"14","author":"S Hoppe","year":"2022","unstructured":"Hoppe S, Meder L, Gebauer F, et al. Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus. Cancers (Basel). 2022;14(19):4789.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1411_CR39","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/jpm13101445","volume":"13","author":"E Liatsou","year":"2023","unstructured":"Liatsou E, Schizas D, Frountzas M. The Impact of Trophoblast Cell-Surface Antigen 2 Expression on the Survival of Patients with Gastrointestinal Tumors: A Systematic Review. J Pers Med. 2023;13(10):1445.","journal-title":"J Pers Med"},{"key":"1411_CR40","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","volume":"12","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Yuan X, Tian Q, et al. Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front Oncol. 2022;12:951589.","journal-title":"Front Oncol"},{"issue":"7Suppl","key":"1411_CR41","doi-asserted-by":"publisher","first-page":"AbstractnrCT038","DOI":"10.1158\/1538-7445.AM2024-CT038","volume":"84","author":"J Rodon","year":"2024","unstructured":"Rodon J, Wainberg ZA, Zhang M, et al. Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a Phase 2 study [abstract]. Cancer Res. 2024;84(7Suppl):AbstractnrCT038.","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"1411_CR42","first-page":"S263","volume":"35","author":"K Shitara","year":"2024","unstructured":"Shitara K, Wainberg ZA, Van Cutsem E, et al. TroFuse-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) vs treatment of physician\u2019s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA). Ann Oncol. 2024;35(Suppl 2):S263. (abstract 263TiP).","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"1411_CR43","first-page":"TPS511","volume":"43","author":"DY Oh","year":"2025","unstructured":"Oh DY, Xu J, Tabernero J, et al. KEYMAKER-U06: Phase 1\/2 umbrella platform study of TROP2 antibody-drug conjugate sacituzumab tirumotecan plus pembrolizumab plus chemotherapy (substudy 06\u00a0C) and sacituzumab tirumotecan plus paclitaxel (substudy 06D) in gastroesophageal adenocarcinoma. J Clin Oncol. 2025;43(suppl 4):TPS511.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1411_CR44","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","volume":"32","author":"A Bardia","year":"2021","unstructured":"Bardia A, Messersmith WA, Kio EA, et al. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial. Ann Oncol. 2021;32(6):746\u201356.","journal-title":"Ann Oncol"},{"issue":"15suppl","key":"1411_CR45","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1200\/jco.2015.33.15_suppl.3546","volume":"33","author":"A Starodub","year":"2015","unstructured":"Starodub A, Ocean AJ, Messersmith WA, et al. Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I\/II clinical experience. J Clin Oncol. 2015;33(15suppl):3546.","journal-title":"J Clin Oncol"},{"key":"1411_CR46","doi-asserted-by":"publisher","first-page":"100051","DOI":"10.1016\/j.esmogo.2024.100051","volume":"4","author":"B Kobitzsch","year":"2024","unstructured":"Kobitzsch B, Stocker G, Hacker UT, et al. SAGA-a phase Ib\/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma. ESMO Gastrointest Oncol. 2024;4:100051.","journal-title":"ESMO Gastrointest Oncol"},{"key":"1411_CR47","doi-asserted-by":"crossref","unstructured":"Egebjerg K, Lordick F, Liu LL, Dahlgaard NB, Mau-S\u00f8rensen M. Zolbetuximab as a gastric lineage-directed immunotherapy: mechanistic rationale and translational evidence in CLDN18.2-positive gastroesophageal adenocarcinoma. Expert Rev Anticancer Ther. 2026;26(7):817\u2013827.","DOI":"10.1080\/14737140.2026.2615855"},{"issue":"1","key":"1411_CR48","doi-asserted-by":"publisher","first-page":"28958","DOI":"10.1038\/s41598-025-12337-4","volume":"15","author":"S Pak","year":"2025","unstructured":"Pak S, Simon AG, Lyu SI, et al. The expression of the tight junction protein and therapeutical target Claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma. Sci Rep. 2025;15(1):28958.","journal-title":"Sci Rep"},{"issue":"4","key":"1411_CR49","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.21037\/jgo-2025-111","volume":"16","author":"S Wallam","year":"2025","unstructured":"Wallam S, Park J, Wu LW, Moy RH. Retrospective analysis of Claudin18.2 expression in ethnically diverse patients with gastroesophageal adenocarcinoma. J Gastrointest Oncol. 2025;16(4):1420\u201333.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"1411_CR50","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/cco-25-39","volume":"14","author":"I Nakayama","year":"2025","unstructured":"Nakayama I. The novel approach with antibody-drug conjugate targeting CLDN18.2 trial\u2019s insights and future perspectives. Chin Clin Oncol. 2025;14(5):61.","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"1411_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","volume":"26","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Liu FR, Wei XL, et al. Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial. Lancet Oncol. 2025;26(2):227\u201338.","journal-title":"Lancet Oncol"},{"issue":"suppl 16","key":"1411_CR52","doi-asserted-by":"publisher","first-page":"TPS3163","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3163","volume":"42","author":"AG Raufi","year":"2024","unstructured":"Raufi AG, Goyal L, Smyth E, et al. CLARITY-PanTumor01: A phase 2 trial of the claudin 18.2-specific antibody-drug conjugate AZD0901 (CMG901) in patients with CLDN18.2-expressing advanced solid tumors. J Clin Oncol. 2024;42(suppl 16):TPS3163.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1411_CR53","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1039\/D4MD00637B","volume":"16","author":"Q Yang","year":"2024","unstructured":"Yang Q, Liu Y. Technical, preclinical, and clinical developments of Fc-glycan-specific antibody-drug conjugates. RSC Med Chem. 2024;16(1):50\u201362.","journal-title":"RSC Med Chem"},{"issue":"9","key":"1411_CR54","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","volume":"31","author":"J Liu","year":"2025","unstructured":"Liu J, Yang J, Sun Y, et al. CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial. Nat Med. 2025;31(9):3028\u201336.","journal-title":"Nat Med"},{"key":"1411_CR55","doi-asserted-by":"publisher","first-page":"1661016","DOI":"10.3389\/fmmed.2025.1661016","volume":"5","author":"M Katoh","year":"2025","unstructured":"Katoh M, Loriot Y, Nakayama I, Hamada A, Shitara K, Katoh M. Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. Front Mol Med. 2025;5:1661016.","journal-title":"Front Mol Med"},{"key":"1411_CR56","doi-asserted-by":"publisher","first-page":"115808","DOI":"10.1016\/j.ejca.2025.115808","volume":"230","author":"C Bai","year":"2025","unstructured":"Bai C, Zheng Y, Sun M, et al. Tecotabart vedotin in Claudin 18.2-positive advanced gastric\/gastroesophageal junction cancer: A Bayesian phase 1\/2 clinical trial. Eur J Cancer. 2025;230:115808.","journal-title":"Eur J Cancer"},{"issue":"9","key":"1411_CR57","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41591-025-03781-w","volume":"31","author":"DY Ruan","year":"2025","unstructured":"Ruan DY, Wu HX, Luo SX, et al. The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial. Nat Med. 2025;31(9):3037\u201346.","journal-title":"Nat Med"},{"issue":"8","key":"1411_CR58","doi-asserted-by":"publisher","first-page":"109489","DOI":"10.4251\/wjgo.v17.i8.109489","volume":"17","author":"Z Wang","year":"2025","unstructured":"Wang Z, Zhang RY, Xu YF, Yue BT, Zhang JY, Wang F. Unmasking immune checkpoint resistance in esophageal squamous cell carcinoma: Insights into the tumor microenvironment and biomarker landscape. World J Gastrointest Oncol. 2025;17(8):109489.","journal-title":"World J Gastrointest Oncol"},{"issue":"7","key":"1411_CR59","doi-asserted-by":"publisher","first-page":"530","DOI":"10.3390\/cells14070530","volume":"14","author":"S Mielcarska","year":"2025","unstructured":"Mielcarska S, Kot A, Kula A, et al. B7H3 in Gastrointestinal Tumors: Role in Immune Modulation and Cancer Progression: A Review of the Literature. Cells. 2025;14(7):530.","journal-title":"Cells"},{"key":"1411_CR60","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.2147\/OTT.S111691","volume":"9","author":"J Song","year":"2016","unstructured":"Song J, Shi W, Zhang Y, Sun M, Liang X, Zheng S. Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis. Onco Targets Ther. 2016;9:6257\u201363.","journal-title":"Onco Targets Ther"},{"issue":"8","key":"1411_CR61","doi-asserted-by":"publisher","first-page":"799","DOI":"10.4251\/wjgo.v13.i8.799","volume":"13","author":"P Rasic","year":"2021","unstructured":"Rasic P, Jovanovic-Tucovic M, Jeremic M, et al. B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors. World J Gastrointest Oncol. 2021;13(8):799\u2013821.","journal-title":"World J Gastrointest Oncol"},{"issue":"12","key":"1411_CR62","first-page":"2646","volume":"7","author":"L Chen","year":"2015","unstructured":"Chen L, Chen J, Xu B, et al. B7-H3 expression associates with tumor invasion and patient\u2019s poor survival in human esophageal cancer. Am J Transl Res. 2015;7(12):2646\u201360.","journal-title":"Am J Transl Res"},{"issue":"1","key":"1411_CR63","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41698-025-01011-7","volume":"9","author":"S Marchesi","year":"2025","unstructured":"Marchesi S, Marinello A, Ambrosini P, Cavalli C, Lo Russo G, Occhipinti M. Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment. NPJ Precis Oncol. 2025;9(1):219.","journal-title":"NPJ Precis Oncol"},{"issue":"6","key":"1411_CR64","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med. 2025;31(6):1949\u201357.","journal-title":"Nat Med"},{"issue":"25","key":"1411_CR65","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.1080\/14796694.2025.2565995","volume":"21","author":"TK Owonikoko","year":"2025","unstructured":"Owonikoko TK, Byers L, Cheng Y, et al. IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer. Future Oncol. 2025;21(25):3275\u201382.","journal-title":"Future Oncol"},{"key":"1411_CR66","doi-asserted-by":"publisher","first-page":"S1315","DOI":"10.1016\/j.annonc.2024.07.717","volume":"35","author":"T Doi","year":"2024","unstructured":"Doi T, Patel MR, Koyama T, et al. PS3-3 Clinical and biomarker data from a phase 1\/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors. Ann Oncol. 2024;35:S1315.","journal-title":"Ann Oncol"},{"issue":"16suppl","key":"1411_CR67","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1200\/JCO.2025.43.16_suppl.3035","volume":"43","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Liang X, Huang Y, et al. Results from a phase 1\/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors. J Clin Oncol. 2025;43(16suppl):3035.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1411_CR68","first-page":"355","volume":"12","author":"R Mishra","year":"2018","unstructured":"Mishra R, Patel H, Alanazi S, Yuan L, Garrett JT. HER3 signaling and targeted therapy in cancer. Oncol Rev. 2018;12(1):355.","journal-title":"Oncol Rev"},{"issue":"16suppl","key":"1411_CR69","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1200\/JCO.2022.40.16_suppl.1002","volume":"40","author":"I Krop","year":"2022","unstructured":"Krop I, et al. Results from the phase 1\/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). J Clin Oncol. 2022;40(16suppl):1002.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1411_CR70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s13577-025-01206-x","volume":"38","author":"T Urano","year":"2025","unstructured":"Urano T, Yokota E, Iwai M, et al. Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability. Hum Cell. 2025;38(3):72.","journal-title":"Hum Cell"},{"issue":"25","key":"1411_CR71","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1080\/14796694.2025.2561539","volume":"21","author":"T Powles","year":"2025","unstructured":"Powles T, Bhatia A, Burtness B, et al. HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. Future Oncol. 2025;21(25):3283\u201392.","journal-title":"Future Oncol"},{"issue":"7","key":"1411_CR72","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3390\/biomedicines13071598","volume":"13","author":"C Zhang","year":"2025","unstructured":"Zhang C, Liu Y, Guo H, et al. Interleukin 21-Armed EGFR-VHH-CAR-T Cell Therapy for the Treatment of Esophageal Squamous Cell Carcinoma. Biomedicines. 2025;13(7):1598.","journal-title":"Biomedicines"},{"issue":"6","key":"1411_CR73","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/carcin\/bgad038","volume":"44","author":"D Chen","year":"2023","unstructured":"Chen D, Hong R, Cao Y, et al. Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma. Carcinogenesis. 2023;44(6):451\u201362.","journal-title":"Carcinogenesis"},{"issue":"5","key":"1411_CR74","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41416-025-03093-3","volume":"133","author":"LC Spender","year":"2025","unstructured":"Spender LC, Watt DM, Baxter MA, et al. AKT\/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma. Br J Cancer. 2025;133(5):709\u201322.","journal-title":"Br J Cancer"},{"issue":"7","key":"1411_CR75","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/ijc.28771","volume":"135","author":"CD Fichter","year":"2014","unstructured":"Fichter CD, Timme S, Braun JA, et al. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. Int J Cancer. 2014;135(7):1517\u201330.","journal-title":"Int J Cancer"},{"issue":"7","key":"1411_CR76","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25(7):901\u201311.","journal-title":"Lancet Oncol"},{"key":"1411_CR77","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-019-0824-z","volume":"19","author":"H Deng","year":"2019","unstructured":"Deng H, Shi H, Chen L, Zhou Y, Jiang J. Over-expression of Nectin-4 promotes progression of esophageal cancer and correlates with poor prognosis of the patients. Cancer Cell Int. 2019;19:106.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"1411_CR78","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.3390\/ijms26073200","volume":"26","author":"W Roma\u0144czyk","year":"2025","unstructured":"Roma\u0144czyk W, Pryczynicz A. The Significance of Nectin Family Proteins in Various Cancerogenous Processes. Int J Mol Sci. 2025;26(7):3200.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1411_CR79","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","volume":"76","author":"PM Challita-Eid","year":"2016","unstructured":"Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. Cancer Res. 2016;76(10):3003\u201313.","journal-title":"Cancer Res"},{"issue":"11","key":"1411_CR80","doi-asserted-by":"publisher","first-page":"105806","DOI":"10.1016\/j.esmoop.2025.105806","volume":"10","author":"K Muro","year":"2025","unstructured":"Muro K, Chin K, Maron SB, et al. Phase II trial of enfortumab vedotin in patients with previously treated gastric and esophageal cancers. ESMO Open. 2025;10(11):105806.","journal-title":"ESMO Open"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01411-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01411-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T21:02:34Z","timestamp":1788642154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01411-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01411-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"19 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"46"}}